Vector BioMed, a mission-driven contract vector development and manufacturing organization (CVDMO) dedicated to expanding access to cell and gene therapies, has announced a strategic partnership with Muni Seva Ashram’s Kailash Cancer Hospital and Research Center (KCHRC) in Gujarat, India. Through this collaboration, Vector BioMed becomes the exclusive CVDMO partner for KCHRC’s pioneering cell therapy program—aimed at bringing cost-effective CAR-T cancer treatments to underserved populations.
The partnership, initiated in June 2024, follows over a year of in-depth due diligence, site visits, and technical reviews led by KCHRC’s leadership, including Dr. Vikram Patel. KCHRC is expected to begin treating patients with autologous CAR-T therapies in early 2026, making it the first center in Gujarat—and among the first in India outside a major metro area—to offer this cutting-edge treatment.
Vector BioMed brings to the partnership its innovative portfolio of rapid CAR-T solutions, including prebuilt, validated anti-CD19 CAR-T constructs and other IND-ready formats. The company’s approach simplifies the manufacturing process, reduces timelines, and enhances the global standard of care—making advanced cancer therapies more accessible to hospitals and research institutions.
Situated in rural Gujarat, KCHRC provides care to over 70,000 outpatients annually, with more than 60% receiving free or donor-subsidized treatment. Operated under the umbrella of Muni Seva Ashram—a nonprofit committed to equitable healthcare—the hospital is equipped with 400 beds, 10 operating theatres, three linear accelerators, and expanding GMP capabilities, positioning it as a rising regional leader in precision oncology and advanced therapeutics.
“We are honored to partner with Muni Seva Ashram in this impactful mission,” said Dr. Boro Dropulić, CEO of Vector BioMed. “This collaboration is a meaningful step toward democratizing access to one of the most advanced cancer treatments available today. Together, we are working to ensure that geography or financial status no longer limits access to world-class care.”
The initiative is powered by Vector BioMed’s LENTIVERSE™ platform—a versatile, scalable, and cost-efficient system optimized for the needs of low- and middle-income countries (LMICs). Capable of treating one patient per day without reliance on proprietary high-cost technologies, LENTIVERSE™ helps institutions like KCHRC scale advanced therapies sustainably and affordably.
“This partnership moves us closer to our vision of making cutting-edge cancer care universally accessible,” said Dr. Vikram Patel, Chair of Muni Seva Ashram. “Vector BioMed’s expertise in vector manufacturing and clinical support has been instrumental in building our cell therapy program, and will soon be life-changing for the communities we serve.”